Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients

Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients

Show other versions (1)

Bibliographic Details
Main Authors:	Christine M. Sorenson, Zafer Gurel, Yong-Seok Song, Kyle D. Peterson, Barbara A. Blodi, Nader Sheibani
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10896504/?tool=EBI

Similar Items

Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients.
by: Christine M Sorenson, et al.
Published: (2024-01-01)

Targeted Thrombospondin-1 Expression in Ocular Vascular Development and Neovascularization
by: Christine M. Sorenson, et al.
Published: (2021-04-01)

Associations of ARMS2 and CFH Gene Polymorphisms with Neovascular Age-Related Macular Degeneration
by: Supanji S, et al.
Published: (2021-03-01)

Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
by: Oyuna S. Kozhevnikova, et al.
Published: (2022-07-01)

CFH Y402H polymorphism and response to intravitreal Ranibizumab in brazilian patients with neovascular age-related macular degeneration
by: Carlos Eduardo Veloso, et al.

Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking.
by: Anne E Hughes, et al.
Published: (2007-12-01)

Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD)
by: Nur Afiqah Mohamad, et al.
Published: (2018-08-01)

Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration.
by: Moreno Menghini, et al.
Published: (2012-01-01)

Choroidal Mast Cells and Pathophysiology of Age-Related Macular Degeneration
by: Sara Malih, et al.
Published: (2023-12-01)

Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021-09-01)

CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study.
by: Bénédicte M J Merle, et al.
Published: (2015-01-01)

Oxidative stress-induced premature senescence dysregulates VEGF and CFH expression in retinal pigment epithelial cells: Implications for Age-related Macular Degeneration
by: Mariela C. Marazita, et al.
Published: (2016-04-01)

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
by: Yingbin Fu, et al.
Published: (2024-02-01)

Bim Expression Promotes the Clearance of Mononuclear Phagocytes during Choroidal Neovascularization, Mitigating Scar Formation in Mice
by: Shoujian Wang, et al.
Published: (2022-01-01)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
by: Kabanarou SA, et al.
Published: (2017-05-01)

Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments
by: Rehan M. Hussain, et al.
Published: (2021-12-01)

rs3753394 Complement Factor H (CFH) Gene Polymorphism in Patients with Age-Related Macular Degeneration (AMD) in Indonesian Population
by: Supanji Supanji, et al.
Published: (2021-01-01)

VEGF Inhibition Associates With Decreased Risk of Mortality in Patients With Neovascular Age-related Macular Degeneration
by: Benjamin Sommer Thinggaard, MD, et al.
Published: (2024-05-01)

Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
by: Tobias Strunz, et al.
Published: (2022-05-01)

Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration
by: Jing Wu, et al.
Published: (2022-04-01)

Association of CFH and MAP1LC3B gene polymorphisms with age-related macular degeneration in a high-altitude population
by: Rui-Juan Guan, et al.
Published: (2022-11-01)

Histology of neovascular myopic macular degeneration
by: Shefali B. Jonas, et al.
Published: (2021-11-01)

Haplotypes in the complement factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration.
by: Peter J Francis, et al.
Published: (2007-11-01)

Impact of Anti-VEGF Treatment and Patient Characteristics on Vision Outcomes in Neovascular Age-related Macular Degeneration
by: Charles C. Wykoff, MD, PhD, et al.
Published: (2024-03-01)

Melatonin Inhibits VEGF-Induced Endothelial Progenitor Cell Angiogenesis in Neovascular Age-Related Macular Degeneration
by: Liang-Wei Lin, et al.
Published: (2023-03-01)

Long-Term Outcomes of Nonadherence to Anti-VEGF Therapy in Advanced Neovascular Age-Related Macular Degeneration
by: A. N. Kulikov, et al.
Published: (2022-10-01)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
by: Fangyuan Han, et al.
Published: (2022-11-01)

Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration.
by: Yusuke Arai, et al.
Published: (2020-01-01)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
by: Akira Hirata, et al.
Published: (2018-03-01)

Lens status influences the association between CFH polymorphisms and age-related macular degeneration: findings from two population-based studies in Singapore.
by: Chee Wai Wong, et al.
Published: (2015-01-01)

Clinical efficacy and changes of serum VEGF-A, VEGF-B, and PLGF after conbercept treating neovascular age-related macular degeneration
by: Xiao-Dong Chen, et al.
Published: (2023-09-01)

Caffeine Inhibits Choroidal Neovascularization Through Mitigation of Inflammatory and Angiogenesis Activities
by: Christine M. Sorenson, et al.
Published: (2021-10-01)

Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration.
by: Saleh, Rafidah, et al.
Published: (2017)

Suspension of Anti-VEGF Treatment Does Not Affect Expansion of RPE Atrophy in Neovascular Age-Related Macular Degeneration
by: Shinichiro Chujo, et al.
Published: (2023-05-01)

Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration
by: Bo Hee Kim, et al.
Published: (2023-06-01)

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
by: R. R. Fayzrakhmanov
Published: (2019-06-01)

OCT-Derived Radiomic Features Predict Anti–VEGF Response and Durability in Neovascular Age-Related Macular Degeneration
by: Sudeshna Sil Kar, PhD, et al.
Published: (2022-12-01)

Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy
by: Xuan Cao, et al.
Published: (2022-01-01)

A novel small molecule anti-VEGF drug Brolucizumab in the treatment of neovascular age-related macular degeneration
by: Tong Wu, et al.
Published: (2022-05-01)